Clinicopathologic and Genomic Analysis of TP53 -Mutated Endometrial Carcinomas

Amir Momeni Boroujeni, Wissam Dahoud, Chad Vanderbilt, Sarah Chiang, Rajmohan Murali, Eric Rios‐Doria, Kaled M. Alektiar, Carol Aghajanian, Nadeem R. Abu‐Rustum, Marc Ladanyi, Lora H. Ellenson, Britta Weigelt, Robert A. SoslowClinical 2021 · DOI

Abstract

<i>TP53</i>-mutated endometrial carcinomas display clinical and molecular similarities across histologic subtypes. Our data provide evidence to suggest performance of <i>ERBB2</i> assessment in all <i>TP53</i>-mutated endometrial carcinomas. Given the distinct clinical features of serous carcinomas, histologic classification continues to be relevant.
BibTeX
@inproceedings{boroujeni2021clinicopathologic,
  author = {Amir Momeni Boroujeni and Wissam Dahoud and Chad Vanderbilt and Sarah Chiang and Rajmohan Murali and Eric Rios‐Doria and Kaled M. Alektiar and Carol Aghajanian and Nadeem R. Abu‐Rustum and Marc Ladanyi and Lora H. Ellenson and Britta Weigelt and Robert A. Soslow},
  title = {{Clinicopathologic and Genomic Analysis of <i>TP53</i> -Mutated Endometrial Carcinomas}},
  booktitle = {Clinical},
  year = {2021},
  doi = {10.1158/1078-0432.ccr-20-4436},
}

Loading related content...

Figure